Treatment for Pertussis
Azithromycin is the first-line antibiotic for treating pertussis across all age groups, with age-specific dosing regimens that prioritize safety and efficacy. 1
Primary Treatment Approach
The cornerstone of pertussis treatment is macrolide antibiotic therapy, which eradicates Bordetella pertussis from the nasopharynx and reduces transmission, though it does not shorten the disease course or improve symptoms once the paroxysmal stage has begun. 2, 3
First-Line Agent: Azithromycin
Azithromycin is preferred over other macrolides due to its superior safety profile, convenient once-daily dosing, and shorter treatment duration. 1
Age-specific dosing regimens: 1
- Infants <6 months: 10 mg/kg per day for 5 days
- Infants and children ≥6 months: 10 mg/kg (maximum 500 mg) on day 1, then 5 mg/kg per day (maximum 250 mg) on days 2-5
- Adults: 500 mg on day 1, then 250 mg per day on days 2-5
Critical safety consideration for neonates (<1 month): Azithromycin is the only recommended macrolide for this age group because erythromycin carries a significant risk of infantile hypertrophic pyloric stenosis (IHPS). 1 The risk of severe pertussis complications in neonates outweighs the theoretical IHPS risk with azithromycin, which has not been associated with IHPS to date. 1 However, all infants <1 month receiving any macrolide should be monitored for IHPS and other serious adverse events. 1
Alternative Macrolides
Clarithromycin is an acceptable alternative for patients >1 month old: 1
- Infants and children >1 month: 15 mg/kg per day (maximum 1 g per day) in 2 divided doses for 7 days
- Adults: 1 g per day in 2 divided doses for 7 days
- Contraindicated in infants <1 month due to unknown IHPS risk 1
Erythromycin is no longer preferred due to higher adverse event rates and requires a longer 14-day course: 1
- Infants >1 month and children: 40-50 mg/kg per day (maximum 2 g per day) in 4 divided doses for 14 days
- Adults: 2 g per day in 4 divided doses for 14 days
- Not preferred for infants <1 month due to documented IHPS risk (relative risk: infinity in one cohort study) 1
Alternative for Macrolide Intolerance or Resistance
Trimethoprim-sulfamethoxazole (TMP-SMZ) is the alternative when macrolides are contraindicated, not tolerated, or when macrolide-resistant B. pertussis is suspected: 1
- Contraindicated in infants <2 months due to kernicterus risk 1
- Infants ≥2 months and children: Trimethoprim 8 mg/kg per day + sulfamethoxazole 40 mg/kg per day in 2 divided doses for 14 days
- Adults: Trimethoprim 320 mg per day + sulfamethoxazole 1,600 mg per day in 2 divided doses for 14 days
Important caveat: Macrolide resistance is emerging as a significant concern, with 98% resistance reported in China and spreading to other countries. 4 If macrolide resistance is suspected or confirmed, TMP-SMZ becomes the treatment of choice for eligible patients. 1
Key Clinical Considerations
Timing of Treatment
Antibiotics are most effective when initiated during the catarrhal stage (first 1-2 weeks) before paroxysmal coughing begins. 3, 5 Once the paroxysmal stage is established, antibiotics will not improve symptoms or shorten disease duration but remain indicated to prevent transmission. 2, 3
Drug Interactions and Precautions
Azithromycin-specific warnings: 1
- Avoid concurrent use with aluminum- or magnesium-containing antacids (reduces absorption)
- Use caution in patients with impaired hepatic function
- Monitor when used with drugs metabolized by cytochrome P450 (digoxin, triazolam, ergot alkaloids)
Erythromycin and clarithromycin carry more significant drug interaction risks due to CYP3A inhibition and should not be used with astemizole, cisapride, pimozide, or terfenadine due to risk of cardiac arrhythmias. 1
Common Pitfalls to Avoid
Do not use erythromycin in neonates unless azithromycin is absolutely unavailable, and if used, closely monitor for IHPS signs (projectile vomiting, feeding difficulties). 1
Do not use TMP-SMZ in infants <2 months, pregnant women, or nursing mothers due to kernicterus risk. 1
Do not delay treatment while awaiting laboratory confirmation if clinical suspicion is high during the catarrhal stage. 3, 5
Recognize that antibiotics do not improve symptoms once paroxysmal coughing has begun - set appropriate patient expectations. 2, 5
Pregnancy Considerations
- Azithromycin is FDA Pregnancy Category B (preferred in pregnancy) 1
- Erythromycin is FDA Pregnancy Category B 1
- Clarithromycin is FDA Pregnancy Category C (avoid if possible) 1
- TMP-SMZ is FDA Pregnancy Category C and contraindicated 1
Postexposure Prophylaxis
The same antibiotic regimens used for treatment apply to postexposure prophylaxis for household contacts and high-risk individuals (infants, immunocompromised, third-trimester pregnancy, or those in close contact with high-risk persons). 2 Azithromycin remains the preferred agent. 1, 2